PDL BioPharma recently reported strong Q217 earnings mainly due to royalties related to the authorized generic of Glumetza as well as an increase in the fair value of the Depomed royalty assets as a whole. Also, LENSAR, which became a wholly-owned subsidiary on 11 May, was consolidated in the results, with $2.6m in revenues and $3.8m in expenses. The company continues to receive royalty payments for Tysabri for longer than expected; it was paid $16.3m in Q217.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs